Results 161 to 170 of about 319,869 (211)
Some of the next articles are maybe not open access.
Best Practice & Research Clinical Endocrinology & Metabolism, 2004
Endocrine therapy remains a cornerstone of systemic therapy for breast cancer even though it was first introduced more than a century ago. In the past three decades a large number of randomized trials involving several tens of thousands of patients have been performed to determine the role of endocrine therapy in the adjuvant setting.
openaire +2 more sources
Endocrine therapy remains a cornerstone of systemic therapy for breast cancer even though it was first introduced more than a century ago. In the past three decades a large number of randomized trials involving several tens of thousands of patients have been performed to determine the role of endocrine therapy in the adjuvant setting.
openaire +2 more sources
2018
The use of hormonal therapy in breast cancer has improved the overall outcome for patients with early-stage hormone receptor-positive disease. The choice of hormone therapy is related to multiple factors, including menopausal state, patient preference, and potential side effects.
Rena, Shah, Ruth M, O'Regan
openaire +2 more sources
The use of hormonal therapy in breast cancer has improved the overall outcome for patients with early-stage hormone receptor-positive disease. The choice of hormone therapy is related to multiple factors, including menopausal state, patient preference, and potential side effects.
Rena, Shah, Ruth M, O'Regan
openaire +2 more sources
Postoperative Adjuvant Therapy
Scandinavian Journal of Gastroenterology, 1988There is no proven significant benefit of adjuvant chemotherapy in colorectal cancer. Portal infusion of 5-FU in the immediate postoperative period has given some promising results but further trials of this treatment are necessary. Intraperitoneal administration should also be tested.
openaire +2 more sources
Hematology/Oncology Clinics of North America, 2021
as adjuvant therapy for high-risk melanoma was extensively studied in regimens that varied by dosage, route of administration, formulation, and therapy duration. The high-dose regimen (HDI) showed significant improvements in relapse-free survival (RFS) in 3 trials and overall survival (OS) in 2.
openaire +2 more sources
as adjuvant therapy for high-risk melanoma was extensively studied in regimens that varied by dosage, route of administration, formulation, and therapy duration. The high-dose regimen (HDI) showed significant improvements in relapse-free survival (RFS) in 3 trials and overall survival (OS) in 2.
openaire +2 more sources
Perspectives for Adjuvant Therapy
Surgical Clinics of North America, 1981Future trends in adjuvant therapy appear to be directed toward better selection of patients by more sophisticated and sensitive methods, improved selection and integration of adjuvant modalities, prediction of the toxicity associated with adjuvant therapy, and the introduction of new agents and modalities to treat minimal residual neoplastic disease.
M W, Burk, D L, Morton
openaire +2 more sources
Current Treatment Options in Oncology, 2019
In recent years, the number of patients with malignant melanoma has continued to increase globally; surgery remains the first treatment option for patients with resectable melanoma. Adjuvant therapy for patients with stage III and IV melanoma following surgical resection has gradually been approved. After complete resection, these patients can probably
Maiko, Wada-Ohno +2 more
openaire +2 more sources
In recent years, the number of patients with malignant melanoma has continued to increase globally; surgery remains the first treatment option for patients with resectable melanoma. Adjuvant therapy for patients with stage III and IV melanoma following surgical resection has gradually been approved. After complete resection, these patients can probably
Maiko, Wada-Ohno +2 more
openaire +2 more sources
Neoadjuvant Therapy Versus Adjuvant Therapy
2012This chapter describes an aspect of study design for oncology clinical trials (and in daily oncology clinical practice), namely, the choice of neoadjuvant therapy, which occurs before surgery, and adjuvant therapy, which occurs after therapy. Neoadjuvant therapy and adjuvant therapy each have specific advantages.
openaire +1 more source
Seminars in Cutaneous Medicine and Surgery, 2003
The incidence of melanoma is rapidly increasing, especially in younger female and older male patients. Recent fundamental advances in our knowledge of melanoma tumorigenesis have established roles for inhibitors of the MAPK pathway and regulatory immune checkpoints CTLA-4 and PD-1/PD-L1.
Larisa, Geskin +2 more
openaire +2 more sources
The incidence of melanoma is rapidly increasing, especially in younger female and older male patients. Recent fundamental advances in our knowledge of melanoma tumorigenesis have established roles for inhibitors of the MAPK pathway and regulatory immune checkpoints CTLA-4 and PD-1/PD-L1.
Larisa, Geskin +2 more
openaire +2 more sources
Oncology Research and Treatment, 2003
Despite intensive research and numerous clinical trials on the adjuvant treatment of patients with high-risk cutaneous melanoma, the issue is still controversial. Early positive results from studies on adjuvant chemo- and immunotherapy were based on historical controls and could not be confirmed by prospective randomized trials.
P, Mohr, M, Weichenthal, A, Hauschild
openaire +2 more sources
Despite intensive research and numerous clinical trials on the adjuvant treatment of patients with high-risk cutaneous melanoma, the issue is still controversial. Early positive results from studies on adjuvant chemo- and immunotherapy were based on historical controls and could not be confirmed by prospective randomized trials.
P, Mohr, M, Weichenthal, A, Hauschild
openaire +2 more sources
Esophageal Cancer: Adjuvant Therapy
The Cancer Journal, 2007In the United States, esophageal cancer is an uncommon but aggressive malignancy. Prior research has focused on the incorporation of chemotherapy and radiotherapy in both the pre- and postoperative setting. Both squamous cell and adenocarcinoma histologies have been treated in trials, with adenocarcinoma now the predominant histology seen in the United
Geoffrey Y, Ku, David H, Ilson
openaire +2 more sources